STERIS (NYSE:STE) Earns “Market Outperform” Rating from JMP Securities

STERIS (NYSE:STE)‘s stock had its “market outperform” rating restated by investment analysts at JMP Securities in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $265.00 target price on the medical equipment provider’s stock. JMP Securities’ price objective points to a potential upside of 18.76% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Stephens restated an “overweight” rating and issued a $240.00 target price on shares of STERIS in a research report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Piper Sandler raised their price target on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $258.75.

STERIS Trading Down 1.0 %

Shares of NYSE:STE opened at $223.13 on Thursday. The firm has a market capitalization of $22.03 billion, a price-to-earnings ratio of 50.94 and a beta of 0.84. The business’s 50 day moving average price is $212.49 and its 200-day moving average price is $224.60. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. STERIS has a 1 year low of $197.82 and a 1 year high of $248.24.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.02% and a return on equity of 13.78%. On average, equities research analysts forecast that STERIS will post 9.11 earnings per share for the current fiscal year.

Insider Buying and Selling at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $217.32, for a total transaction of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.14% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of STE. Ashton Thomas Securities LLC acquired a new stake in shares of STERIS during the third quarter worth about $25,000. Human Investing LLC acquired a new stake in shares of STERIS in the 4th quarter valued at $31,000. Anfield Capital Management LLC lifted its position in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 91 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in shares of STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC increased its holdings in STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 137 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.